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AKT1 fails to replicate as a longevity-associated gene
in Danish and German nonagenarians and
centenarians
Marianne Nygaard*,1,2, Mette Soerensen1,2, Friederike Flachsbart3, Jonas Mengel-From1,2, Qihua Tan1,2,
Stefan Schreiber3, Almut Nebel3, Kaare Christensen1,2,4 and Lene Christiansen1,2
In addition to APOE and FOXO3, AKT1 has recently been suggested as a third consistent longevity gene, with variants in AKT1
found to be associated with human lifespan in two previous studies. Here, we evaluated AKT1 as a longevity-associated gene
across populations by attempting to replicate the previously identified variant rs3803304 as well as by analyzing six additional
AKT1 single-nucleotide polymorphisms, thus capturing more of the common variation in the gene. The study population was
2996 long-lived individuals (nonagenarians and centenarians) and 1840 younger controls of Danish and German ancestry. None
of the seven SNPs tested were significantly associated with longevity in either a case–control or a longitudinal setting, although
a supportive nominal indication of a disadvantageous effect of rs3803304 was found in a restricted group of Danish
centenarian men. Overall, our results do not support AKT1 as a universal longevity-associated gene.
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INTRODUCTION
Despite the fact that approximately 25% of variation in human
lifespan is attributable to genetic factors,1 polymorphisms in only a
few candidate genes have so far been consistently found to be
associated with longevity.
The first to be discovered, and also the most prominent candidate,
is the apolipoprotein E (APOE) gene. The APOE e4 haplotype
has repeatedly been reported as an age-related mortality factor in
numerous populations,2 and recently, the APOE e4 allele was
confirmed to negatively affect survival into old age in two genome-
wide association studies (GWASs).3,4
The forkhead box O3 (FOXO3) gene, which encodes a transcription
factor involved in the insulin/insulin-like growth factor 1 (IGF1)
pathway, has been presented as another well-established candidate.
The insulin/IGF1 pathway has repeatedly been implicated in longevity
in various model organisms,5 as well as in humans, where the FOXO3
association has been demonstrated in a number of populations of
diverse ethnic origin.6–11
The newest candidate that has been put forward as a third
consistent longevity gene is AKT1, which is also part of the insulin/
IGF1 pathway. Single-nucleotide polymorphisms (SNPs) in this gene
have been associated with longevity in two studies: in 2009,
Pawlikowska et al9 described the variant rs3803304 as influencing
human lifespan in three different cohorts consisting of participants
from the Study of Osteoporotic Fractures and the Cardiovascular
Health Study, as well as Ashkenazi Jewish Centenarians, whereas the
SNP rs2498804 was detected in a recent GWAS of Dutch
nonagenarians from the Leiden Longevity Study.3
In this study, we evaluated AKT1 as a longevity-associated gene
across populations by analyzing rs3803304 in a large sample of Danish
and German long-lived individuals with the aim of replicating the
previous finding. Further, we included six additional AKT1 SNPs in
order to cover more of the common variation within the gene.
MATERIALS AND METHODS
Study populations
Danish study. The Danish study population comprised 1383 participants
from The Danish 1905 Birth Cohort Study, described in details elsewhere.12
Briefly, the study was initiated in 1998, when participants were 92–93 years of
age and follow-up studies of surviving participants were carried out in 2000,
2003 and 2005, when participants reached 100 years of age.
Genotyping of the candidate SNP rs3803304 was performed in all 1383
participants, of which 190 individuals (women proportion of 80%) lived to be
at least 100 years of age, whereas genotype information on the six additional
SNPs was available for 1089 individuals as previously described.13 A total of
143 of the 1089 individuals (women proportion of 79%) lived to be at least
100 years of age.
Vital status was followed until death or until 1 January 2011, resulting in a
mean follow-up time for survivors of 12.4 years (range: 12.2–12.6). Informa-
tion on survival status was retrieved from the Danish Central Population
Register, which is continuously updated.14
A group of 736 younger control individuals (mean age 50.6 years) were
randomly selected from the population-based study of middle-aged Danish
twins,15 which was initiated in 1998 with the random selection of 2640 intact
twin pairs born from 1931 to 1952. Here, only one twin from each pair was
included.
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German study. The German study population included 865 nonagenarians
and 748 centenarians (age range 95–110 years, mean age 98.9 years, women
proportion of 73.0% in all cases and 80.5% in centenarians). The control
individuals were 1104 younger unrelated individuals (age range 60–75 years,
mean age 67.2 years). The participants were recruited from different
geographic regions of Germany and were all of German ancestry.16
Study approvals were received from the Danish National Committee on
Biomedical Research Ethics and the Ethics Committee of the University
Hospital Schleswig-Holstein, respectively.
Genotyping
The primary SNP for association testing was rs3803304. In addition to this, six
supplementary variants, which had previously been selected for coverage of the
common genetic variation in AKT1 using data from the International HapMap
Project (http://hapmap.ncbi.nlm.nih.gov/index.html.en), were included.
Genotyping of rs3803304 in the Danish study population and of rs3803304,
rs2494731, rs2494732, rs2498796, rs2494738 and rs1130214 in the German
study population was performed using predesigned TaqMan SNP genotyping
assays (Applied Biosystems, Pleasonton, CA, USA). The SNP rs2494748 could
not be genotyped in the German population because of technical difficulties.
Genotyping of rs2494731, rs2494732, rs2498796, rs2494738, rs2494748 and
rs1130214 in the Danish study population was part of a previous study and
was performed using the Illumina GoldenGate Technology (Illumina Inc., San
Diego, CA, USA) as described by Soerensen et al.13
Statistical analysis
All analyses were carried out using the statistical software Stata (Stata version
11.2; Stata Corporation, College Station, TX, USA). Logistic regression was
used to assess the association between genotype and longevity with dose of
minor allele coded as 0, 1 and 2. An additive model was applied to all of the
seven AKT1 SNPs; however, for rs3803304, the potential association with
longevity was further explored using a genotypic, dominant and recessive
model.
Mortality analysis in the Danish 1905 Birth Cohort was performed on all of
the seven AKT1 SNPs using a left-truncated Cox proportional hazards model
to adjust for late entry into the data set according to age.
To account for the multiple testing of seven SNPs, a Bonferroni-corrected
significance level of 0.007 (0.05/7) was applied.
Power calculations were performed using the freely available software
Quanto (Quanto version 1.2.4, http://hydra.usc.edu/gxe/), assuming a 1 in
20 chance of becoming 92–93 years old, a 1 in 400 chance of becoming a
centenarian and a Bonferroni-corrected significance level of 0.007.
RESULTS
Characteristics of the Danish and German study populations are
summarized in Table 1.
All genotyped SNPs were in Hardy–Weinberg equilibrium in both
control groups, except for rs2494738, which displayed an excess of
heterozygotes in the Danish control group (P¼ 0.02).
The set of tested AKT1 SNPs included the candidate variant
rs3803304 and six additional SNPs, of which three are tagging SNPs
(rs2494731, rs2494738 and rs1130214). The remaining SNPs
(rs2494732, rs2498796 and rs2494748) are distributed evenly along
the gene and were added to enable a more comprehensive coverage of
the gene.
Case–control analysis of all SNPs was performed for the Danish
and German population separately, as well as for the combined study
population. The substantial number of individuals in the combined
study population allowed for the detection of effects as small as
OR¼ 1.2 (for rs2494738, OR¼ 1.3 due to a smaller minor allele
frequency) with a power of at least 87%. Applying an additive model,
none of the seven SNPs demonstrated a significant association with
longevity in either of the populations (Table 2).
As rs3803304 was previously found to be associated with longevity,9
it was investigated more thoroughly using a genotypic, dominant and
recessive model. No significant associations were found with any of
the models applied (data not shown).
To scrutinize for potential effects of variation in AKT1 on extreme
survival, the analysis was next restricted to include centenarians only
(Table 3), resulting in the ability to detect effects of size OR¼ 1.25
(for rs2494738, OR¼ 1.4) in the combined study population with a
power of at least 80%. One nominally significant indication
(P¼ 0.03) of a disadvantageous effect of rs3803304 on longevity
was found in Danish men, and this indication was supported when
applying genotypic and dominant models (P¼ 0.02 and 0.01,
respectively).
In addition to applying a cross-sectional approach, the effects of the
seven SNPs on survival during old age were investigated in the Danish
1905 Birth Cohort. Regardless of the genetic model applied, no
associations with survival during the follow-up of 412 years were
found. Restriction of analysis to include centenarians only did not
change this result (data not shown).
DISCUSSION
AKT1 has recently been suggested as a third universal longevity gene,
together with APOE and FOXO3. To further elucidate this potential
role of AKT1, case–control studies involving Danish and German
long-lived individuals and younger controls were performed. In
addition to the previously described candidate variation rs3803304,9
our study was expanded to include a number of additional SNPs to
ensure better coverage of the known allelic variance in AKT1.
The main finding of this study was a lack of formal replication of
the association of rs3803304 with longevity as previously found in
three independent populations.9 In the initial report by Pawlikowska
et al,9 they found that the association with longevity appeared driven
by the minor allele homozygous genotype, as subjects homozygous
for the minor allele were underrepresented among long-lived cases.
In line with this, restricting the analysis to centenarians revealed a
trend of supportive evidence in Danish men, with the same direction
of effect as identified before.9 It should be noted, though, that the
sample size of the refined group of centenarian men was very limited
(n¼ 37), and when applying a Bonferroni correction for multiple
statistical testing, the association did not remain significant.
To facilitate a more exhaustive exploration of the possible relevance
of AKT1 variations in longevity, six additional SNPs available from a
previous study13 were included and tested in both the Danish and
German study population. Of note, one of these, rs2494731, is in
perfect linkage disequilibrium with the AKT1 SNP rs2498804, which
was recently found to be associated with lifespan in a population
of Dutch nonagenarians.3 Nevertheless, we did not replicate an
association with longevity, whether applying a cross-sectional
Table 1 Characteristics of the study populations
Danish study population German study population
Cases Controls Cases Controls
Number, LLI 1383/1089a 736 1613 1104
Women, LLI (%) 70.7/71.3a 49.6 73.0 74.4
Age at intake, LLI 92–93 46–55 95–110 60–75
Number, centenarians 190/143a — 748 —
Women, centenarians (%) 80.0/79.0a — 80.5 —
Abbreviation: LLI, long-lived individuals.
aThe number to the left applies to rs3803304.
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Table 2 Association analysis of AKT1 variations in long-lived individuals
Danish population German population Combined population
SNP Sex
MAF
Cases/controls OR 95% CI P
MAF
Cases/controls OR 95% CI P
MAF
Cases/controls OR 95% CI P
rs3803304 All 0.25/0.27 0.93 0.80–1.08 0.320 0.27/0.26 1.03 0.91–1.17 0.610 0.26/0.26 0.99 0.90–1.09 0.784
Men 0.25/0.28 0.87 0.69–1.09 0.229 0.28/0.26 1.09 0.84–1.41 0.515 0.26/0.27 0.96 0.81–1.14 0.673
Women 0.25/0.26 0.97 0.80–1.18 0.779 0.26/0.26 1.02 0.88–1.18 0.831 0.26/0.26 1.00 0.89–1.12 0.967
rs2494731 All 0.34/0.34 1.00 0.87–1.17 0.953 0.36/0.35 1.05 0.94–1.17 0.393 0.35/0.34 1.03 0.94–1.13 0.503
Men 0.32/0.35 0.87 0.69–1.11 0.266 0.36/0.33 1.12 0.90–1.39 0.296 0.34/0.34 1.01 0.86–1.18 0.893
Women 0.34/0.32 1.10 0.91–1.34 0.324 0.36/0.35 1.02 0.90–1.17 0.714 0.35/0.34 1.04 0.93–1.16 0.472
rs2494732 All 0.43/0.43 0.99 0.86–1.14 0.879 0.46/0.44 1.06 0.95–1.18 0.296 0.45/0.44 1.04 0.95–1.13 0.406
Men 0.39/0.43 0.81 0.64–1.02 0.073 0.46/0.42 1.13 0.92–1.39 0.253 0.43/0.43 0.99 0.85–1.15 0.928
Women 0.45/0.42 1.12 0.94–1.34 0.214 0.46/0.45 1.03 0.91–1.17 0.594 0.45/0.44 1.06 0.95–1.17 0.287
rs2498796 All 0.30/0.32 0.92 0.79–1.07 0.292 0.32/0.31 1.03 0.92–1.16 0.575 0.31/0.32 0.99 0.90–1.08 0.788
Men 0.29/0.34 0.80 0.63–1.02 0.075 0.33/0.31 1.10 0.88–1.37 0.411 0.31/0.32 0.96 0.81–1.12 0.573
Women 0.30/0.30 1.01 0.83–1.23 0.912 0.32/0.32 1.01 0.88–1.16 0.877 0.31/0.31 1.00 0.90–1.12 0.949
rs2494738 All 0.12/0.12 0.99 0.79–1.23 0.912 0.08/0.07 1.06 0.87–1.29 0.581 0.10/0.09 1.03 0.89–1.19 0.718
Men 0.12/0.13 0.92 0.66–1.29 0.645 0.07/0.07 0.97 0.66–1.44 0.893 0.09/0.11 0.87 0.68–1.12 0.275
Women 0.12/0.12 1.04 0.77–1.39 0.799 0.08/0.07 1.09 0.86–1.38 0.473 0.10/0.09 1.12 0.93–1.34 0.221
rs2494748 All 0.34/0.35 0.95 0.82–1.09 0.466
Men 0.35/0.36 0.96 0.77–1.20 0.728
Women 0.33/0.35 0.94 0.78–1.13 0.510
rs1130214 All 0.31/0.31 1.05 0.91–1.23 0.498 0.30/0.31 0.94 0.83–1.05 0.258 0.30/0.31 0.97 0.89–1.07 0.544
Men 0.32/0.31 1.06 0.83–1.34 0.653 0.28/0.31 0.86 0.69–1.09 0.214 0.30/0.31 0.94 0.79–1.10 0.429
Women 0.31/0.30 1.05 0.86–1.28 0.612 0.31/0.31 0.96 0.84–1.10 0.557 0.31/0.31 0.99 0.89–1.10 0.842
Abbreviations: CI, confidence interval; MAF, minor allele frequency; OR, odds ratio (applying an additive model).
Cases are long-lived individuals with an age of 492 years at intake in the Danish population and 495 years in the German population. P-values are uncorrected.
Table 3 Association analysis of AKT1 variations in centenarians
Danish population German population Combined population
SNP Sex
MAF
Cases/controls OR 95% CI P
MAF
Cases/controls OR 95% CI P
MAF
Cases/controls OR 95% CI P
rs3803304 All 0.23/0.27 0.81 0.61–1.06 0.126 0.26/0.26 1.00 0.86–1.17 0.993 0.26/0.26 0.95 0.83–1.08 0.443
Men 0.16/0.28 0.49 0.26–0.94 0.033 0.26/0.26 1.00 0.70–1.41 0.980 0.25/0.27 0.84 0.63–1.12 0.230
Women 0.24/0.26 0.92 0.67–1.25 0.590 0.26/0.26 1.00 0.84–1.19 0.982 0.26/0.26 0.98 0.85–1.14 0.821
rs2494731 All 0.32/0.34 0.97 0.72–1.30 0.821 0.35/0.35 1.01 0.88–1.16 0.871 0.34/0.34 1.01 0.90–1.15 0.837
Men 0.29/0.35 0.75 0.39–1.42 0.373 0.33/0.33 0.98 0.73–1.31 0.869 0.32/0.34 0.91 0.70–1.18 0.479
Women 0.33/0.32 1.04 0.75–1.44 0.826 0.36/0.35 1.02 0.87–1.20 0.786 0.35/0.34 1.05 0.91–1.20 0.534
rs2494732 All 0.43/0.43 1.01 0.76–1.33 0.957 0.45/0.44 1.03 0.90–1.17 0.684 0.44/0.44 1.03 0.92–1.16 0.580
Men 0.35/0.43 0.69 0.38–1.26 0.224 0.44/0.42 1.05 0.79–1.38 0.741 0.40/0.43 0.97 0.77–1.24 0.830
Women 0.45/0.42 1.12 0.82–1.54 0.468 0.45/0.45 1.02 0.88–1.19 0.776 0.45/0.44 1.05 0.92–1.20 0.454
rs2498796 All 0.28/0.32 0.85 0.63–1.14 0.276 0.32/0.32 0.99 0.86–1.15 0.931 0.31/0.32 0.97 0.85–1.10 0.602
Men 0.27/0.34 0.69 0.37–1.30 0.253 0.31/0.31 1.01 0.75–1.35 0.957 0.30/0.32 0.90 0.70–1.17 0.446
Women 0.28/0.30 0.90 0.64–1.26 0.545 0.32/0.32 0.99 0.84–1.16 0.898 0.31/0.31 0.99 0.86–1.14 0.865
rs2494738 All 0.13/0.12 1.14 0.76–1.72 0.525 0.07/0.07 1.00 0.78–1.29 0.990 0.10/0.09 0.91 0.74–1.12 0.368
Men 0.20/0.13 1.68 0.84–3.38 0.142 0.03/0.07 0.88 0.51–1.54 0.663 0.11/0.11 0.82 0.54–1.24 0.346
Women 0.11/0.12 0.95 0.58–1.57 0.853 0.08/0.07 1.03 0.78–1.37 0.811 0.10/0.09 0.94 0.74–1.20 0.631
rs2494748 All 0.37/0.35 1.11 0.85–1.45 0.443
Men 0.41/0.36 1.23 0.71–2.13 0.457
Women 0.37/0.35 1.08 0.79–1.46 0.643
rs1130214 All 0.33/0.31 1.13 0.84–1.51 0.431 0.29/0.31 0.95 0.83–1.10 0.502 0.31/0.31 0.98 0.87–1.11 0.754
Men 0.30/0.31 0.97 0.54–1.76 0.926 0.28/0.31 0.88 0.64–1.20 0.416 0.31/0.31 0.89 0.69–1.16 0.389
Women 0.33/0.30 1.18 0.84–1.66 0.334 0.31/0.31 0.97 0.83–1.14 0.736 0.31/0.31 1.01 0.88–1.16 0.907
Abbreviations: CI, confidence interval; MAF, minor allele frequency; OR, odds ratio (applying an additive model).
Cases are restricted to individuals living to an age of Z100 years. P-values are uncorrected.
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approach or taking advantage of the longitudinal data with412 years
of follow-up available for the Danish nonagenarian sample.
In conclusion, despite a substantial power, we did not confirm
AKT1 as a longevity-associated gene in populations of Danish and
German nonagenarians and centenarians. This finding does not
necessarily rule out a potential relevance of AKT1 in longevity. First,
population genetic differences may explain the lack of replication,
although this explanation is not very likely, because all analyzed
populations were of European ancestry. Second, because our coverage
of allelic variation in AKT1 is probably not complete, other variations
that are not tagged by the included SNPs may be associated with
survival differences. However, all in all, our results do suggest that
AKT1 is not a universally acting longevity gene.
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